Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. - Wikidata - awgldk - TriplyDB

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

http://www.wikidata.org/entity/Q34351552

about

Creating an effective clinical registry for rare diseases Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives The Immunogenetics of Autoimmune Cholestasis Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis.Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II.Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.Liver Transplantation for Cholestatic Liver Diseases in Adults Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up.Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study-CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study I National incidence of autoimmune liver diseases and its relationship with the human development index.Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.Surgical treatment of intrahepatic cholangiocarcinoma in the USA.Outcomes in liver transplantation: does sex matter?Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol.Screening for malignancy in primary sclerosing cholangitis (PSC).Inflammatory Bowel Disease with Primary Sclerosing Cholangitis: a Danish Population-based Cohort Study 1977-2011.Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.Primary sclerosing cholangitis: a clinical update.Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.The management of autoimmunity in patients with cholestatic liver diseases.The Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report from the NASPGHAN Pancreas Committee.New approach to decrease post-ERCP adverse events in patients with primary sclerosing cholangitis.Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?Recommendations on the use of MRI in PSC-A position statement from the International PSC study group.Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.

P2860

Q26741126-A3EE2C66-D600-4557-A326-DA05389C32ED Q26781780-E4C682A6-02A7-4870-B662-FDB83C89D1F3 Q26782878-2812A726-570E-44F8-9B7F-81C271B237DA Q26796355-4AA62865-4891-4DE4-8732-625FDDC45EB5 Q28085134-3903BA96-4161-424D-809E-41DA58C6E44F Q28085346-CFFEE490-966C-4894-86E5-5F4835C7E597 Q34403316-37458A47-1FBF-4BF4-A938-2C8C9AF16C1F Q35146460-1DD2EF04-39D1-4810-9CBD-37E64D47D499 Q35470575-E5C59234-622C-42D4-ABE4-516F7CAFEADA Q35535485-55743CCB-4C9A-460B-A6A0-343ACE6409C6 Q35810359-E9C85838-D768-44D5-AE9C-01A8F868105E Q36025017-BF5E5B2A-498B-4FE7-82FA-BCE89DE156A6 Q36199767-AAE1CA26-B6BC-44F4-A92E-C2C73ECFA7E5 Q36320523-525C09C6-27D9-4620-A3F5-B3179872CF81 Q36325130-B5A597C3-4D04-4FD9-AD2F-ED346856AE94 Q36693626-47E27862-0773-4B54-88B6-4784ECE11409 Q36752084-9455ADAF-69CC-47F1-80B4-29E190AA3A3C Q36805289-D50D9985-5039-4B9D-AC3D-53BAE7396DB8 Q37000684-0EACA19C-1DBF-46BC-9DAE-A013922595B3 Q37082378-3DE20BBA-FFE7-4EB5-A8C7-FB3BE4DFAEA5 Q37454003-82BDD75E-B98F-4386-9BAF-30C9962EB585 Q37564713-E7B5CA95-08E7-438B-870C-C8C59C0FD5A4 Q37584099-6D49D2A2-2AE6-4E77-B284-DE2B4FA5A9F4 Q37710785-EB15A247-39D5-42B7-BD34-623401A65302 Q38174167-8F57A285-CD7C-413D-9FA6-ED3D475EB890 Q38245994-8500BAAF-0ACD-43E3-8E8E-2E0BCE96E567 Q38272589-2C99D598-E3C4-444F-9A2A-5F3A81881977 Q38356761-565035BC-D5D9-47A4-9305-0979C84C7F66 Q38374581-93AA8AEE-7CDA-49B6-B36E-0B192C257B66 Q38383074-C6C24298-E8C7-44B1-9413-5E5CF75CB259 Q38399155-D219014E-58D7-4092-B8A7-47089E0D4174 Q38412069-A6F946C0-3926-4CD4-925F-81212BD608D9 Q38485235-B1C35E13-BB77-4971-93C7-F0AF76FAD4BE Q38595151-2EED0635-4FF0-408F-95C6-38C6EA47FF1C Q38622370-70E00505-D769-460F-8286-FC0371A3ADAE Q38637770-3A44289B-96AA-4A86-A4A5-0F4A5D73CE0A Q38645109-331DFA89-98C8-4F9D-9780-21412071E463 Q38657903-CDB68C99-9FE4-4FF0-975A-DB87DDEFD9AE Q38677506-7F1D6C46-CF6C-4E2A-8DC4-70B549267FD8 Q38732987-02C97054-BCE9-43AC-A1ED-0A335C65F2BF

P2860

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

http://www.wikidata.org/entity/Q34351552

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@ast

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@en

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@nl

type

label

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@ast

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@en

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@nl

prefLabel

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@ast

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@en

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@nl

P1433

Q34351552-197B7FDB-48C7-4F4D-AE0B-2A0D510EC08C

P1476

Q34351552-657E7D49-A9A8-451C-8CCF-103EF06A44F6

P2093

Q34351552-01AB6785-125D-4211-A280-BBE7FE392B2F

Q34351552-046463C2-4C26-41E4-AB3A-5EAD8F9C033E

Q34351552-0613A528-CA68-400E-AB13-C496E0B2B6C8

Q34351552-1DBE6943-A36E-42A8-AC9C-B058C7A86473

Q34351552-3364A416-9154-4E89-8C91-52EF5C7771FB

Q34351552-3871ACDB-1835-442F-A010-C7BFB7869E68

Q34351552-6CEC5D11-BFC1-484A-AB1B-DB9865517D12

Q34351552-787B94B5-DA81-448F-970E-6BA8E595DBF3

Q34351552-889358B1-10F8-462D-97A8-EFB231FAF4EA

Q34351552-99603A04-D8AF-441D-8A7E-4EC2253647CC

P2860

Q34351552-0578F6F6-77DF-486A-91A5-261AAF8765D6

Q34351552-06721C2F-151F-4410-B74E-5FA3F6E10A87

Q34351552-1475A50F-82A6-44A7-B0DA-94B09F2A4B48

Q34351552-29490560-66A5-4C10-BA5E-06DCEAB0A787

Q34351552-2FFF89EF-B7E4-4E06-83AD-4E89C14FA7B7

Q34351552-33171EE7-995F-4529-BA7E-676A80D3E80C

Q34351552-3939CC57-75E5-4C5D-8FA6-E30623F9A970

Q34351552-42D9ADC0-5C0E-4A1C-B62B-0881D9084F40

Q34351552-496E0632-B3C2-44DA-85CE-2412D0ACEFB7

Q34351552-49A882DA-68A6-49B5-8FB7-AA547252AB33

P304

Q34351552-233327C5-5CDB-420C-A3B3-FB0CAD6689EF

P31

Q34351552-22C70054-785C-408A-8E4F-D5E9B13074CA

P356

Q34351552-EC2C7795-E6DC-4B7E-8C77-52F9F3E259D1

P407

Q34351552-DE39E2A1-3386-4FFB-83C5-EE1597C8836F

P433

Q34351552-0FE930E6-F59A-4628-B139-280490F0B502

P478

Q34351552-A6E2A494-9CFA-40A7-9599-E23BAEBED301

P577

Q34351552-58AEAF33-F90A-496F-BFFC-1E5312F32C9D

P698

Q34351552-1DCF14D6-7976-4EEE-881A-51C9467A0379

P921

Q34351552-2E42C0D3-3B7E-4B5F-8879-21EAE18D4AB5

Q34351552-843F7ACE-F41B-43FB-97C9-41C3D88F3C64

P356

P1433

P1476

Population-based epidemiology, ...... rimary sclerosing cholangitis.

@en

P2093

Alexander C Poen

http://www.w3.org/2001/XMLSchema#string

Anton H Naber

http://www.w3.org/2001/XMLSchema#string

B W Marcel Spanier

http://www.w3.org/2001/XMLSchema#string

Bart van Hoek

http://www.w3.org/2001/XMLSchema#string

Ben J Witteman

http://www.w3.org/2001/XMLSchema#string

Cyriel Y Ponsioen

http://www.w3.org/2001/XMLSchema#string

EpiPSCPBC Study Group

http://www.w3.org/2001/XMLSchema#string

Erik A Rauws

http://www.w3.org/2001/XMLSchema#string

Frank P Vleggaar

http://www.w3.org/2001/XMLSchema#string

Hans A Tuynman

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review

Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis.

Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population.

Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.

Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.

Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease.

P304

2045-2055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26565

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23775876

http://www.w3.org/2001/XMLSchema#string

P921